A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: KRAS mutations are the key indicator for EGFR monoclonal antibody‐targeted therapy and acquired drug resistance, and their accurate detection is critical to the clinical decision‐making of colorectal cancer. However, no proper quality control material is available for the current detection methods, particularly next‐generation sequencing (NGS). The ideal quality control material for NGS needs to provide both the tumor mutation gene and the matched background genomic DNA, which is uncataloged in public databases, to accurately distinguish germline polymorphisms and somatic mutations. Methods: We developed a novel KRAS G12V mutant cell line using the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR‐associated protein 9 (Cas9) technique to make up for the deficiencies in existing quality control material and further validated the feasibility of the cell line as quality control material by amplification refractory mutation system (ARMS), Sanger sequencing, digital PCR (dPCR), and NGS. Results: We verified that the edited cell line specifically had the G12V mutation, and the validation results presented a high consistency among the four methods of detection. The three cell lines screened contained the G12V mutation and the mutation allele fractions of G12V‐1, G12V‐2, and G12V‐3 were 52.01%, 82.06%, and 17.29%, respectively. Conclusion: The novel KRAS G12V cell line generated using the CRISPR/Cas9 gene editing system is suitable as a quality control material for all current detection methods and provides a new direction in the development of quality control material.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“this technique has been applied in preparing QC materials by introducing a targeted mutation into wild‐type cell lines in several studies.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids
Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., & Sato, T. (2015) · Nature Medicine · doi:10.1038/nm.3802 · Cited by 1,135
Research works printed but not linked: 22
- 10.1056/NEJMoa0804385 · DOI · Paper page
- 10.1038/nature11219 · DOI · Paper page
- 10.1038/nature11156 · DOI · Paper page
- 10.1038/nm.3511 · DOI · Paper page
- 10.1038/bjc.2011.247 · DOI
- 10.1016/j.cca.2012.04.029 · DOI
- 10.1158/1078-0432.CCR-10-3087 · DOI
- 10.1373/clinchem.2013.206359 · DOI · Paper page
- 10.1136/jclinpath-2014-202405 · DOI
- Blons H, 2009, Technical considerations for KRAS testing in colorectal cancer, The biologist's point of view, Bull Cancer, 96, S47
- 10.1093/annonc/mdt153 · DOI
- 10.1016/j.jmoldx.2012.01.002 · DOI
- 10.1093/nar/29.1.308 · DOI · Paper page
- 10.1038/nature11632 · DOI · Paper page
- 10.1186/s12918-016-0300-5 · DOI
- 10.1038/nprot.2013.143 · DOI · Paper page
- 10.3390/ijms17040484 · DOI
- 10.1158/1078-0432.CCR-11-3210 · DOI · Paper page
- 10.1001/jamasurg.2015.0313 · DOI · Paper page
- 10.1136/jcp.2003.011973 · doi:10.1136/jcp.2003.011973
- 10.1373/clinchem.2017.272559 · DOI
- 10.1016/j.jmoldx.2017.06.003 · DOI · Paper page
Cited by
Zhou, L., Li, R., Zhang, R., Peng, R., Chen, K., Gao, P., Zhang, J., Zhang, R., & Li, J. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23256 · Cited by 4
Self-citation
Metadata
- Authors
- Jia, S., Zhang, R., Lin, G., Peng, R., Gao, P., Han, Y., Fu, Y., Ding, J., Wu, Q., Zhang, K., Xie, J., & Li, J.
- Affiliations
- Peking University Fifth School of Clinical Medicine National Center for Clinical Laboratories National Center of Gerontology Beijing Hospital Beijing China
- National Center for Clinical Laboratories National Center of Gerontology Beijing Hospital Beijing China
- ORCID
- Jia, Shiyu
- Venue
- Journal of Clinical Laboratory Analysis
- Publisher
- Wiley
- Published
- 2018-01-30
- Volume
- 32
- Issue
- 5
- ISSN
- 0887-8013
- 1098-2825
- Cited by
- 10
- References
- 1
- Language
- en
- Funders
- National Natural Science Foundation of China (81601848)
- Natural Science Foundation of Beijing Municipality (7174345)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing. https://app.cochat.ai/papers/10.1002/jcla.22391
- The paper
- Jia, S., Zhang, R., Lin, G., Peng, R., Gao, P., Han, Y., Fu, Y., Ding, J., Wu, Q., Zhang, K., Xie, J., & Li, J. (2018). A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.22391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.